RENEW2-Weight loss in people living with overweight/obesity + T2D diabetes following treatment Cagri
Research type
Research Study
Full title
Efficacy and safety of cagrilintide for weight management in participants with overweight or obesity and type 2 diabetes
IRAS ID
1012543
Contact name
Clinical Transparency Dept 2834
Contact email
Sponsor organisation
Novo Nordisk A/S
Eudract number
2024-519530-24
Research summary
Weight loss and thereby reduction in body fat is recommended in the treatment of type 2 diabetes to lower body fat. Exercise and diet can help some people to lower their body weight. Other people need extra treatments to lose weight. Cagrilintide is a medicine that can help people lose weight.
This study will look at the weight loss in participants who take cagrilintide compared to participants who take placebo which looks like the treatment being tested but does not have any active medicine in it. The study will also look at how safe cagrilintide is. Throughout the study the participants will follow diet and exercise plans.REC name
London - Westminster Research Ethics Committee
REC reference
25/LO/0507
Date of REC Opinion
3 Sep 2025
REC opinion
Further Information Favourable Opinion